Find a Clinical Trial

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Observational long-term follow-up study of patients who have been exposed to a gene-modified cell therapy produced by ex vivo transduction of immune cells expressing viral or non-viral vectors in studies sponsored by Sorrento Therapeutics, Inc.

Purpose of Study

Study STI-CELL-102 is an observational study of patients who have been exposed to a gene-modified cell therapy (GMCT) produced by ex vivo transduction of immune cells expressing viral and/or non-viral vectors in studies sponsored by Sorrento Therapeutics, Inc. Patients are to be followed for up to 15 years after exposure to a GMCT agent for the possible development of long-term adverse events and efficacy outcomes.

Eligibility

Sex:
All

Key Inclusion / Exclusion Criteria

Inclusion Criteria:

Patients must have received any amount of a CGT in a study sponsored by Sorrento Therapeutics, Inc.

Exclusion

Exclusion Criteria:

Unable or unwilling to provide written informed consent and/or comply with study requirements.

Conditions:

Status:

Enrolling by invitation

Study ID

NCT05472649

Read Detailed Summary

Start Date / End Date:

16/06/2021 -

Enrollment:

1

Full Details:

https://clinicaltrials.gov/ct2/show/NCT05472649

SELECT * FROM `wp_study_loc_rel` WHERE `study_id`=5413 /* From [sorrentotherapeutics.com/study/long-term-follow-up-of-patients-who-received-gene-modified-cell-therapy/] in [/nas/content/live/jshi/wp-content/themes/sorrento/single-study.php:232] */

1 Study Locations

United States

Abramson Cancer Center Clinical Research Unit, University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States


Study Locations Map: